Loading
Latest filing published 23 Sept 2026 for Pharvaris N.V., €190k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Filings by David W. Nassif span 3 companies, the busiest being Sio Gene Therapies Inc., SteadyMed Ltd. and Pharvaris N.V. In total, 11 filings cover trades dated from 13 November 2017 to 21 September 2026.
Sales make up the whole of the open-market record (4 sales, €361k). Other entries cover 6 share grants. In 2026 alone, the filings show no purchases and 1 sale.
Most recently, on 23 September 2026, the filings show an open-market sale worth €190k in Pharvaris N.V. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations